[S-07] Extending the clinical spectrum of cerebral amyloid angiopathy (CAA)

[S-07-3] Extending the clinical spectrum of cerebral amyloid angiopathy (CAA)

Steven M. Greenberg^1,2 (1.Massachusetts General Hospital, 2.Harvard Medical School)

Cerebral amyloid angiopathy (CAA) , a common finding in the aging brain, is caused by accumulation of amyloid beta protein in the cerebral vasculature. Recent studies have revealed that CAA has a wider clinical spectrum than previously recognized. CAA should be in differential diagnosis of patients with lobar intracerebral hemorrhage, cognitive impairment, transient neurological symptoms, headache, and other neurological manifestations. Understanding of the growing clinical spectrum of CAA would lead to a more appropriate approach towards management of patients with CAA-related neurological disorders. In this symposium, experts in this field discuss (1) the wide clinical spectrum of CAA-related cerebrovascular disorders, (2) CAA-related cognitive impairment and inflammation, and (3) management of CAA, including current clinical implications and future perspectives for therapies against CAA.

Dr. Greenberg is Professor of Neurology at Harvard Medical School, Vice Chair of Neurology for Faculty Development and Promotions, and holds the John J Conway Endowed Chair in Neurology at Massachusetts General Hospital. He is recipient of the 2017 American Heart Association William M. Feinberg Award for excellence in clinical stroke and has served in many national and international leadership roles in the fields of stroke and neurology including principle investigator for the NINDS MarkVCID biomarkers consortium coordinating center, president of the International CAA Association, chair of the NIH Acute Neurologic Injury and Epilepsy study section, co-chair of the NINDS Alzheimer’s Disease-Related Dementias Summit subcommittee on vascular cognitive impairment, and chair of the American Heart Association International Stroke Conference. Dr. Greenberg has authored over 200 peer-reviewed research articles and over 80 chapters, reviews, and editorials in the areas of hemorrhagic stroke and small vessel brain disease. He received his undergraduate degree in Biochemistry from Harvard University and MD and PhD degrees from Columbia University under the graduate research training of Dr. James Schwartz. He performed internship at Pennsylvania Hospital, neurology residency at MGH, and post-doctoral fellowship at Brigham and Women’s Hospital under the training of Dr. Kenneth Kosik.